NEW YORK (AdAge.com) -- Following a review of holding companies, pharmaceutical marketer Schering-Plough has consolidated its estimated $400 million global creative business
|Assignments for Schering-Plough's product lines will be decided this month.
A Schering-Plough representative declined to say which agencies would handle which brands for the marketer, which markets a variety of prescription and over-the-counter drugs, from Levitra, Claritin and Clarinex to skin-care products like Bain de Soleil and Coppertone.
No clear edge
One executive familiar with the matter said a process that would decide assignments would begin this month and that neither of the victorious holding companies emerged with an edge. The review encompassed only prescription drug brands.
Holding company representatives referred calls to Schering-Plough.
Executives close to the review said two other holding compamnies, WPP Group and Havas, as well as the winners, emerged as contenders following initial presentations in Paris in April.
BBDO and Saatchi
Omnicom's BBDO Worldwide already handles Schering's Nasonex brand, while Publicis' Saatchi & Saatchi took over the creative responsibilities for the marketer's erectile dysfunction drug Levitra in September following a review. WPP's Quantum Group had been the brand's agency.
Schering-Plough spent $265 million in measured media in the U.S. in 2003 and $169.6 million from January to July of 2004.
CORRECTION: An earlier version of this story incorrectly reported Schering-Plough's review encompassed both over-the-counter and prescription drug brands. The review was only for the prescription brands.